Forian Inc., a provider of data science driven information and analytics solutions, reported financial results for the fourth quarter and full year ended December 31, 2025. The company demonstrated substantial revenue growth while managing costs and making strategic investments, even as it faces a potential acquisition proposal from an internal consortium.
For the full year 2025, Forian achieved revenue of $30.3 million, representing a 50% increase from $20.2 million in 2024. This growth was driven by key contract renewals that offset industry challenges and expanded market penetration in the pharmaceutical and biotech sectors. The company's net loss improved to $2.9 million compared to $3.8 million in the prior year, while Adjusted EBITDA, a non-GAAP measure, increased 72% to $840,408.
The fourth quarter results showed continued momentum with revenue reaching $8.0 million, a 37% increase from the same period in 2024. However, the quarter resulted in a net loss of $1.8 million, compared to net income of $0.2 million in the prior year period. Adjusted EBITDA for the quarter was negative $170,531 compared to positive $120,599 in the fourth quarter of 2024. The company ended the year with strong liquidity, holding $31.6 million in cash, cash equivalents and marketable securities.
Chief Executive Officer Max Wygod emphasized the company's balanced approach, stating that disciplined cost management and strategic investment went hand in hand throughout 2025. The company expanded into new markets while making targeted investments in its data platform and product development. Forian strengthened its data foundation by expanding contracting activity and onboarding new clinical data feeds, addressing upstream data supply challenges that have impacted the healthcare analytics sector.
Beyond financial performance, Forian faces potential corporate changes. On August 25, 2025, a consortium led by the company's Chief Executive Officer and Executive Chair submitted a non-binding proposal to acquire all outstanding shares not currently owned by the group. A Special Committee formed to evaluate this proposal remains in place and is in discussions with the consortium. The company has stated there can be no assurance that any transaction will result from these discussions. For more detailed financial information, investors can visit the company's website at https://www.forian.com.
The company's performance matters because it reflects the growing demand for sophisticated data analytics in healthcare and life sciences. As pharmaceutical and biotech companies increasingly rely on data-driven insights to optimize operations and measure performance, providers like Forian play a crucial role in transforming raw healthcare data into actionable intelligence. The company's expansion into these sectors indicates broader industry trends toward data integration and analytics adoption.
Forian's financial results also highlight the challenges of balancing growth investments with profitability in the competitive healthcare technology sector. While revenue growth has been strong, the company continues to operate at a net loss, though showing improvement year-over-year. The potential acquisition proposal adds another layer of complexity, suggesting that management sees value in the company's strategic direction that may not be fully reflected in current market valuation.
The implications of Forian's announcement extend to investors, healthcare providers, and life sciences companies that depend on data analytics for decision-making. Strong revenue growth suggests increasing adoption of Forian's solutions, while the ongoing net losses indicate the substantial investments required to compete in this space. The potential acquisition could signal consolidation in the healthcare data analytics market or strategic moves to position the company for its next phase of development. Forian's ability to navigate these dynamics while expanding its data platform and customer base will be critical for its long-term success in an industry where data quality and analytical capabilities increasingly determine competitive advantage.
